📉 Resilient Trader Trade Idea: The Silent Threat to ResMed (RMD)

In partnership with

Win Messi's Game-Worn 800th-Goal Jersey. Free. App Only.

Kalshi is giving away a signed, authenticated jersey from a World Cup legend every single day through July 7. Di María. Ochoa. Dempsey. Modrić. Falcao. Varane. Ferdinand. Villa. One winner per day. And every daily entry stacks toward the grand prize: Messi's actual game-worn jersey, worn when he scored his 800th career goal vs. Panama in 2023. Download the Kalshi app and enter today's giveaway for free. No purchase necessary. Check in every day to stack your entries. Share with a friend for a bonus shot at Messi.

Get the App. Enter Free.

_{Free to enter. App required. No purchase necessary. 18+, U.S. only (excl. NY & FL).}

Resilient Trader is where smart traders come for vetted ideas.

Every week, we cut through the noise and surface opportunities that institutions are already eyeing-but with strategies tailored for retail traders. Road tripping with the fam through South Dakota this week so I didn’t get to watch the market super closely but I have been watching this one for the last month. Today's setup? A bearish thesis on one of the most dominant medical device companies in the world-a company whose biggest threat isn't coming from a competitor, it's coming from a pill.

We’ll cover:

• Why ResMed (RMD) is a Short at $198.99 or better

• The GLP-1 threat that could permanently shrink its future customer funnel

• How to take advantage with a defined-risk bear put spread

🔍 Trade Thesis: ResMed's Biggest Risk Isn't Losing Customers-It's Never Getting Them

ResMed (RMD) is the undisputed king of the sleep apnea market. The company makes CPAP machines, masks, tubing, and the digital health software that ties it all together. It has a near-monopoly on the U.S. market, recurring revenue that most businesses would envy, and a balance sheet that generates nearly $2 billion in annual operating cash flow.

So why are we shorting it?

Because the market may be underestimating how GLP-1 adoption could permanently shrink ResMed's future customer funnel. And when that becomes clear to the broader market, the stock-already down 32% from its 52-week high-could have significantly more downside ahead.

The Core Bearish Thesis:

ResMed generates recurring revenue from CPAP masks, tubing, and replacement supplies. But that recurring business depends on a steady flow of new patients entering the sleep apnea market. GLP-1 weight loss drugs like Zepbound and Lilly's experimental retatrutide could significantly reduce that pipeline by addressing one of the leading causes of obstructive sleep apnea: obesity.

In June 2026, Eli Lilly announced Phase 3 trial results showing that retatrutide reduced moderate-to-severe obstructive sleep apnea severity by 60.6% in adults with obesity-and helped patients lose an average of 70.3 pounds (28.3%) over 80 weeks. Zepbound was already FDA-approved for sleep apnea in December 2024.

As more patients lose meaningful amounts of weight, fewer may develop severe sleep apnea or require CPAP therapy. That means fewer new device sales today and, ultimately, fewer recurring supply sales in the future.

While ResMed's installed base continues to produce solid recurring revenue, investors should focus on new CPAP device growth. Every missed device sale today represents years of lost high-margin replacement revenue down the road.

Adding to the pressure are slowing healthcare utilization trends, potential drug-first treatment strategies from physicians and insurers, and emerging alternatives to CPAP therapy. If these trends continue, ResMed could face slower earnings growth and further valuation compression as investors begin viewing it as a lower-growth medical technology company.

📊 Stock Overview & Key Metrics

Here is a snapshot of where ResMed stands today:

YTD Performance: RMD is down approximately 21% year-to-date, dramatically underperforming the S&P 500, which has returned +19.6% over the same period.

💰 Cash Flow Analysis

ResMed's cash flow profile is genuinely impressive-and this is the one part of the bull case that deserves credit. The company generated $1.89 billion in operating cash flow over the trailing twelve months, and $1.45 billion in levered free cash flow. That is a business that converts earnings into cash at an exceptional rate.

For Q3 FY2026 alone, operating cash flow was $554 million against net income of $399 million-a cash conversion ratio well above 100%. The company has used that cash to fund $262 million in share repurchases and dividends in a single quarter, and has committed to more than $800 million in annual buybacks for fiscal 2027.

The balance sheet is also clean. ResMed holds $1.66 billion in cash against only $843 million in total debt, giving it a net cash position. The current ratio stands at a healthy 3.0x.

The bear case on cash flow is not about today-it is about tomorrow. If new patient starts slow meaningfully over the next two to three years, the recurring revenue engine that drives those cash flows begins to decelerate. Masks and accessories represent the high-margin, high-frequency revenue that keeps the cash flow machine running. Every new CPAP patient that GLP-1 drugs prevent from entering the market is a customer who will never buy those replacement supplies.

📡 Market Sentiment: Analyst Ratings & News Impact

The analyst community is largely still bullish on ResMed, but the cracks are forming.

The consensus remains "Moderate Buy" with an average price target around $250-$265-but that gap between the current price and the consensus target is itself a warning sign. When a stock trades 25-30% below the average analyst target and keeps going lower, it often means the market is pricing in risks that the analysts have not yet fully incorporated into their models.

Short interest is elevated and rising. As of June 30, 2026, short interest stood at 15.1 million shares, or 12.0% of the float-up sharply from 11.88 million shares the prior month. A rising short interest ratio of 9.46 days to cover tells you that sophisticated traders are increasingly betting against this stock.

The key news driver: Morgan Stanley's June 2026 downgrade was a pivotal moment. The firm cited three specific concerns:
(1) near-term margin expansion constraints due to rising component costs and currency headwinds,
(2) the potential re-entry of Philips into the U.S. PAP device market in 2027, and
(3) GLP-1 impacts on the long-term patient funnel. When Morgan Stanley-which was previously a bull-turns cautious, the market pays attention.

📐 Technical Analysis: Price Trends, Indicators & Support/Resistance

The chart tells a bearish story.

Price Action: ResMed peaked at $293.81 in early 2026 and has been in a sustained downtrend ever since. The stock has lost approximately 32% from its highs and is now trading near critical support levels.

Moving Averages:

✅ The stock is trading below its 50-day moving average ($199.88), which has turned into resistance.

✅ The stock is trading well below its 200-day moving average ($236.12), confirming the long-term downtrend.

✅ The 50-day has crossed below the 200-day, forming a "death cross"-a classically bearish technical signal.

Key Levels:

✅ Resistance: $200-$205 (50-day MA zone), then $220, then $236 (200-day MA)

✅ Support: $180 (52-week low area), then $160-$165 (next major support zone)

✅ RSI: Neutral to slightly oversold, suggesting the stock is not yet at an extreme that would trigger a major bounce.

The Setup: The stock is sitting right at its 50-day moving average, which is now acting as resistance. A failure to reclaim $205 on a rally would be a strong signal that the downtrend remains intact and the next leg lower is beginning.

⚔️ Compare Assets: Market Share & Financial Metrics vs. Key Competitors

ResMed does not operate in a vacuum. Here is how it stacks up against its key competitors and the broader threat landscape.

The Competitive Landscape Is Shifting:

ResMed currently controls approximately 50% or more of the U.S. CPAP device market and has benefited enormously from Philips' recall of its CPAP devices in 2021. That recall handed ResMed a near-monopoly for several years. But Philips is preparing to re-enter the U.S. market in 2027, and Morgan Stanley has explicitly flagged this as a headwind that will limit multiple re-rating.

Meanwhile, Inspire Medical (INSP) is growing rapidly with its hypoglossal nerve stimulation device-a surgical implant that treats sleep apnea without a mask. While still a small player, Inspire represents the type of alternative therapy that could capture CPAP-resistant patients who might otherwise have been ResMed customers.

And then there is the GLP-1 wildcard. Eli Lilly and Novo Nordisk are not traditional medical device competitors, but they are competing for the same patients. If a physician can prescribe Zepbound and potentially eliminate a patient's need for CPAP therapy, that is a lost customer for ResMed-not just for the device, but for years of high-margin mask and accessory resupply.

💎 Value Investor: Intrinsic Value, Growth Potential & Risk Factors

Intrinsic Value Assessment:

Multiple DCF models suggest a fair value range for ResMed of approximately $200-$275 per share, depending on the growth assumptions used. At the current price of $198.99, the stock appears to be trading near the lower end of that range.

The problem with most DCF models is that they are backward-looking-they extrapolate historical growth rates into the future. If GLP-1 adoption meaningfully reduces the new patient funnel, the revenue growth assumptions embedded in those models are too optimistic.

Growth Potential:

ResMed's management has outlined a 2030 strategy targeting sustained double-digit revenue growth and continued margin expansion. The company has also diversified into Residential Care Software (which generated $170 million in Q3 2026 revenue) and recently acquired Noctrix Health for $340 million to expand into restless legs syndrome treatment.

However, the core sleep and breathing health segment-which accounts for approximately 88% of total revenue-remains heavily dependent on new CPAP patient starts.

Key Risk Factors:

1. GLP-1 Patient Funnel Disruption: The most significant long-term risk. If 25-30 million Americans are on GLP-1 drugs by 2030 (per J.P. Morgan estimates), and a meaningful percentage of those patients would have otherwise developed severe sleep apnea, the total addressable market for CPAP therapy shrinks permanently.

2. Philips Re-entry: Philips is expected to re-enter the U.S. PAP device market in 2027. ResMed's market share and pricing power will face pressure for the first time in years.

3. Margin Compression: Rising component costs, currency headwinds, and increased SG&A spending (up 11% in Q3 2026) could compress margins even as revenue grows.

4. Reimbursement Risk: Insurers and payers may increasingly prefer drug-first treatment protocols for sleep apnea in obese patients, reducing CPAP prescriptions.

5. Valuation Multiple Compression: As the market digests these risks, RMD's P/E multiple could compress from the current 17-19x toward the 12-14x range more typical of slower-growth medical device companies.

🧠 Investment Thesis: SWOT Analysis & Recommendations

SWOT Analysis

⚡ Strengths:

• Dominant market position with 50%+ U.S. CPAP market share

• Exceptional cash flow generation ($1.9B operating cash flow TTM)

• High gross margins (62%) driven by software and recurring supplies

• Strong brand recognition among sleep physicians and DME providers

• Diversified revenue with Residential Care Software (12% of revenue)

• Net cash balance sheet with $1.66B in cash vs. $843M in debt

👎 Weaknesses:

• Heavy revenue concentration in sleep and breathing health (88% of revenue)

• Dependence on new patient starts to drive future recurring revenue

• Limited pricing power as CPAP devices face commoditization risk

• High SG&A growth (up 11% year-over-year) pressuring operating leverage

🚀 Opportunities:

• Digital health and AI-powered remote patient monitoring expansion

• International market penetration (only 30% of sleep apnea patients are currently diagnosed)

• Restless legs syndrome market via Noctrix acquisition (17M addressable U.S. patients)

• GLP-1 co-prescription data suggests existing patients may show higher CPAP adherence

⚠️ Threats:

• GLP-1 drugs reducing the new patient pipeline for CPAP therapy

• Philips re-entering the U.S. market in 2027

• Inspire Medical's hypoglossal nerve stimulation as a CPAP alternative

• Potential insurer preference for drug-first sleep apnea treatment protocols

• Rising component costs and currency headwinds compressing margins

• Valuation multiple compression as growth expectations are revised lower

Recommendations for Different Investor Types

For the Bearish Trader (Our Recommendation):
Short RMD at $198.99 or better, with a stop at $210. The technical setup is bearish, the fundamental headwinds are real, and the market is beginning to price in the GLP-1 risk. The bear put spread outlined below offers a defined-risk way to profit from continued weakness.

For the Long-Term Value Investor:
Wait. The stock is not cheap enough to justify the risk. At 17x forward earnings, you are paying a premium for a business whose growth trajectory is genuinely uncertain. A better entry would be in the $150-$160 range, where the GLP-1 risk is more fully priced in.

For the Income Investor:
The 1.2% dividend yield is not compelling enough to compensate for the downside risk. The payout ratio is low (22%), so the dividend is safe, but this is not a yield story.

For the Neutral Investor:
Watch and wait. The Q4 FY2026 earnings call (August 6, 2026) will be critical. Listen for any commentary on new patient starts and device unit volumes. A slowdown in those metrics would be a strong confirmation of the bearish thesis.

💥 Trade of the Week: Buy SJM Stock + Sell Covered Calls

We're combining a straight equity short position with a defined-risk options trade for leveraged downside.

🟢 Trade Setup

• $RMD ( ▼ 1.86% )  at $198.99 or better

This is the cleaner version of the trade for investors who want to short the stock directly and avoid options complexity.

🛡️ Options Play: Bear Put Spread

• Buy the Jan. 15, 2027 $200 Put for $18.80

• Sell the Jan. 15, 2027 $170 Put for $6.90

• Net Debit: $11.90 per share

• Contract Cost: $1,190 per contract

• Expiration: January 15, 2027

📈 Risk-Reward

📊 Payoff Table at Expiration (Jan. 15, 2027)

How the spread works: You are buying the right to sell RMD at $200 and simultaneously selling the right to sell RMD at $170. The $6.90 credit from the short put reduces your cost from $18.80 to $11.90. Your maximum profit is capped at the $30 spread width minus the $11.90 you paid, giving you $18.10 per share. Your maximum loss is the $11.90 you paid. The trade profits once RMD falls below $188.10 at expiration.

🛑 Risk Management Tip

If shorting the stock directly, use the $210 area as your stop loss. A decisive break above the 50-day moving average and the $205-$210 resistance zone would invalidate the near-term bearish setup.

For the bear put spread, your risk is strictly defined to the $1,190 debit paid per contract. Size the position so that if the spread expires worthless, it represents no more than 1-2% of your total portfolio. Long-dated spreads give you time for the thesis to play out, but they are unforgiving if the stock rallies sharply.

🚀 Catalysts on the Horizon

Keep your eyes on:

1. Q4 FY2026 Earnings (August 6, 2026): Watch closely for any commentary on new device unit volumes and new patient starts. A slowdown in these metrics would be a strong confirmation of the bearish thesis.

2. GLP-1 Data Readouts: Continued positive clinical data from Lilly's retatrutide program and broader GLP-1 adoption statistics will keep pressure on the stock.

3. Philips Re-entry Timeline: Any news accelerating Philips' return to the U.S. CPAP market will be viewed negatively for ResMed's market share and pricing power.

4. Analyst Estimate Revisions: Following Morgan Stanley's lead, watch for other analysts to cut their long-term growth assumptions as they digest the GLP-1 structural threat.

5. Insurance Coverage Decisions: If major insurers begin adopting drug-first protocols for obese sleep apnea patients, that would be a significant negative catalyst.

🧠 Final Thoughts

$RMD is a classic case of a high-quality business facing a paradigm shift in its addressable market.

ResMed's management argues-with some supporting data-that GLP-1 co-prescriptions actually drive higher CPAP adherence among existing patients. And there is truth to that. But the more important question is not about the existing installed base. It is about the future patient funnel. If 25-30 million Americans are on GLP-1 drugs by 2030, and a meaningful percentage of those patients would have otherwise developed severe sleep apnea, the total addressable market for CPAP therapy is structurally smaller than the models assume.

Add in Philips' return to the market, rising component costs, and a valuation that still reflects a high-growth compounder, and the risk is heavily skewed to the downside.

The market has already taken notice-RMD is down 32% from its highs while the S&P 500 is up nearly 20% year-to-date. But we think there is more to go.

✅ Short RMD at $198.99 or better
💸 Buy the Jan. 15, 2027 $200/$170 Bear Put Spread for a $11.90 debit

We'll be watching this one closely.

Want more trade ideas like this - plus weekly options plays and breakdowns?

👉 Join the Paid Resilient Trader Newsletter

For more in-depth trading strategies and market insights, upgrade to the paid version of our newsletter.

Our paid newsletter gives you:

• Weekly stock + options trade ideas

  • Market commentary and macro insights

    • Easy-to-follow setups with defined risk

Stay Liquid, my friends
- The Resilient Trader